QIAGEN to submit conditional voluntary takeover offer for shares of Exiqon A/S

31-Mar-2016 - QIAGEN N.V. announced that it has decided to submit a conditional voluntary takeover offer to the shareholders of Exiqon A/S to purchase all shares in Exiqon. The acquisition is expected to expand QIAGEN’s leadership position in Sample to Insight solutions for RNA analysis. This announcement is ...

Michael Kallelis to manage Exiqon's new us facility

Exiqon's US operations will start Q1 2006

09-Jan-2006 - Exiqon A/S announced the appointment of Michael Kallelis as President and General Manager of Exiqon's new US operations. Mr. Kallelis will have the overall responsibility for launching and operating Exiqon's US office to be located in the Boston area. A key focus of the new facility will be to ...

Exiqon A/S wins prestigious Ernst & Young Entrepreneur of the Year Award

24-Nov-2005 - Exiqon A/S announced that it has won the Ernst & Young Entrepreneur Of The Year award in the category Biotech 2005. The prestigious award is created to identify and acknowledge the most successful and entrepreneurial Danish companies. A minimum growth of 15% in sales as well as growth in staff ...

U.S. Genomics Licenses Locked Nucleic Acid (LNA(TM)) Chemistries from Exiqon

LNA(TM) chemistries included in Trilogy(TM) platform reagent kits for microRNA analysis

16-Apr-2004 - Woburn and Copenhagen. U.S. Genomics and Exiqon have entered into a worldwide license agreement to incorporate Exiqon's Locked Nucleic Acid (LNA(TM)) chemistries into reagent kits for the U.S. Genomics Trilogy(TM) platform. Introduced into the market early last month, the Trilogy(TM) platform can ...